Data patterns are predictors of glaucoma medication use

Article

Research investigating the epidemiology of IOP-lowering medication use in the U.S. population will hopefully suggest targets for efforts designed to improve medication access and patient care, one expert says.

Boston-Research investigating the epidemiology of IOP-lowering medication use in the U.S. population will hopefully suggest targets for efforts designed to improve medication access and patient care, said Mark Swanson, OD, MSPH, at the annual meeting of the American Academy of Optometry.

The study analyzed pooled data from two capture periods (2005-2006 and 2007- 2008) of the National Health and Nutrition Examination Survey (NHANES). The database was searched for ophthalmic drugs used for IOP-lowering. Estimates of distribution were calculated for glaucoma drug usage and medication type across various sociodemographic subgroups, and multivariate regression analyses were conducted to identify associations between sociodemographic variables and glaucoma medication use.

NHANES study data

Based on the NHANES methodology, its database is considered a good resource for estimating usage of IOP-lowering medications in the population and sociodemographic variables associated with its use. However, Dr. Swanson acknowledged there are some limitations.

Results of the multivariate model showed the likelihood of glaucoma medication use increased with increasing age and was significantly greater among African-Americans compared with whites, while individuals at the near poverty level were significantly less likely to be using medications for IOP-lowering compared with a reference group in the highest income category, reported Dr. Swanson, associate professor of optometry, and chief, ocular disease service, School of Optometry, University of Alabama at Birmingham.

Recent Videos
In 2 weeks, the study participant's dry eye symptoms improved from 76 to 43 on a 0-100 rating scale, according to Marc-Matthias Schulze, PhD, Dipl Ing.
Eye care practitioners reported moderate to high satisfaction with lifitegrast's ability to improve signs of dry eye, according to Melissa Barnett, OD, FAAO, FSLS.
Neda Gioia, OD, CNS, FOWNS, details the positive feedback gained so far from other optometrists that have been prescribing the NutriTears supplement to their dry eye patients.
Damaris Raymondi, OD, FAAO, highlighted the importance of building patient-doctor trust to learn about these practices, which can include non-traditional treatments like chamomile or manuka honey eye drops.
Noreen Shaikh, OD, Magdalena Stec, OD, FAAO, and Brenda Bohnsack, MD, PhD, emphasize that collaboration and communication are key to proper diagnosis and treatment.
Cecilia Koetting, OD, FAAO, DipABO, cited data from a recent student that found that presbyopia treatment with 0.4% pilocarpine led to up to 86% of patients achieving 20/40 or better.
Kerry Giedd, OD, MS, FAAO, was 1 of 20 investigators around the country for a study evaluating the daily disposable contact lens.
According to A. Paul Chous, MA, OD, FAAO, optometrists have an important opportunity to educate patients in their chairs about diabetes.
David Geffen, OD, FAAO, gave a poster presentation titled "Revolutionizing Comfort: Unveiling the Potential of Perfluorohexyloctane Eyedrops for Contact Lens Wearers" at this year's Academy meeting.
Jessica Steen, OD, FAAO, Dipl-ABO, discussed ophthalmic considerations for patients undergoing treatment with antibody drug conjugates for gynecologic cancers at this year's conference.
© 2024 MJH Life Sciences

All rights reserved.